Efficacy and safety of the S1P receptor agonist ONO-4641 in patients with relapsing-remitting multiple sclerosis: Results of a 26-week, double-blind, placebo-controlled, phase II trial (DreaMS)

Authors
Category Primary study
ConferenceMultiple Sclerosis
Year 2012
This article has no abstract
Epistemonikos ID: 27a15f7d326f59fd7082eacdf635e216faacf4ea
First added on: Apr 30, 2026